A/(H3N2)-LIKE VIRUS ANTIGEN

Clinical trials of A/(H3N2)-LIKE VIRUS ANTIGEN are studying influenza vaccine responses in adults aged 50 years and older. These studies look at immunogenicity, which means how well the vaccine helps the body make antibodies, and safety. The main groups are healthy adults and adults with stable health conditions that raise the risk of influenza complications.

Related diseases and areas:

• Influenza

A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181)

Clinical trials investigating A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181) focus on immune response to influenza vaccination. The studies mainly evaluate antibody levels and how well people respond after vaccination, especially health care personnel. These trials help researchers measure protection against current and past influenza strains.

Related diseases and areas:

• Bacterial infection
• Influenza

A/Darwin/6/2021(H3N2)-Like Strain (A/Darwin/11/2021, Wild Type)

Clinical trials are currently underway to assess the effectiveness and safety of an influenza vaccine containing the A/Darwin/6/2021(H3N2)-Like Strain. This strain, specifically A/Darwin/11/2021 (Wild Type), is one of four viral components in the Flucelvax Tetra vaccine. The trials aim to provide valuable insights into the vaccine’s ability to protect against seasonal influenza, particularly the H3N2 subtype.

Related diseases and areas:

• Multiple sclerosis relapse

A/DARWIN/9/2021 (H3N2) – LIKE STRAIN (A/DARWIN/6/2021, IVR-227)

Clinical trials are studying A/DARWIN/9/2021 (H3N2) – LIKE STRAIN (A/DARWIN/6/2021, IVR-227) as part of influenza vaccine research, mainly in adults and older adults. These studies look at immune response, safety, and how well different vaccine versions work in healthy people and in some higher-risk groups.

Related diseases and areas:

• COVID-19
• Influenza

A/DARWIN/9/2021 (H3N2) – LIKE STRAIN (A/NORWAY/16606/2021, MEDI 355293)

Clinical trials are investigating A/DARWIN/9/2021 (H3N2) – LIKE STRAIN (A/NORWAY/16606/2021, MEDI 355293) to compare immune responses after influenza vaccination. The study looks at safety-related trial outcomes and how well the body makes antibodies in healthy people. It focuses on adults who can receive either an intranasal or intramuscular influenza vaccine.

Related diseases and areas:

• Influenza

A/H1N1 INFLUENZA VACCINE

A/H1N1 INFLUENZA VACCINE is being studied in clinical trials to see how well it works and how safe it is in older adults. These trials mainly look at immune response, lot-to-lot consistency, and comparisons with other influenza vaccines in people aged 50 years and older, including those with stable health conditions.

Related diseases and areas:

• Influenza

A/TEXAS/50/2012 (H3N2) – DERIVED STRAIN USED (NYMC X-223)

Clinical trials investigating A/TEXAS/50/2012 (H3N2) – DERIVED STRAIN USED (NYMC X-223) look at immune responses after influenza vaccination in health care personnel. The main goal is to measure antibody levels and other signs of humoral immunity (antibody-based immunity) against current, past, and circulating influenza strains.

Related diseases and areas:

• Influenza
• Bacterial infection

A/TURKEY/TURKEY/1/05 (H5N1)-LIKE STRAIN (NIBRG-23)

Clinical trials investigating A/TURKEY/TURKEY/1/05 (H5N1)-LIKE STRAIN (NIBRG-23) are studying avian influenza vaccine immunity in adults. The main goals are to measure immune response, including safety-related study outcomes only as stated in the trial data, and to compare responses to avian and seasonal influenza vaccines. The trial is in Phase 3 and includes about 300 participants.

Related diseases and areas:

• Influenza

A/Victoria/2570/2019 (H1N1)Pdm09-Like Strain (A/Victoria/2570/2019, Ivr-215)

This article summarizes several clinical trials investigating the use of influenza vaccines containing the A/Victoria/2570/2019 (H1N1)pdm09-like strain. These trials aim to evaluate the safety, immunogenicity, and effectiveness of various influenza vaccine formulations in different populations, including older adults, patients with hematological cancers, and the general adult population. The studies compare high-dose and standard-dose vaccines, as well as different administration methods and combinations with other vaccines.

Related diseases and areas:

• Influenza
• Colorectal cancer
• COVID-19

A/Victoria/4897/2022 (H1N1)Pdm09-Like Strain (A/Victoria/4897/2022, Ivr-238)

This article summarizes clinical trials investigating the use of influenza vaccines containing the A/Victoria/4897/2022 (H1N1)pdm09-like strain. These trials aim to evaluate the safety, efficacy, and immunogenicity of various influenza vaccine formulations in different age groups. The studies compare adjuvanted and non-adjuvanted vaccines, as well as novel mRNA-based vaccines, to assess their potential in preventing seasonal influenza.

Related diseases and areas:

• COVID-19
• Influenza

A/Wisconsin/67/2022 (H1N1)Pdm09-Like Strain (A/Georgia/12/2022 Cvr-167)

This article discusses the use of the A/Wisconsin/67/2022 (H1N1)Pdm09-Like Strain (A/Georgia/12/2022 CVR-167) in clinical trials for influenza vaccines. This strain is one of the components in the Flucelvax Tetra vaccine, which is being studied to assess its safety, effectiveness, and long-term outcomes in preventing influenza.

Related diseases and areas:

• Multiple sclerosis relapse

A24110He

A new clinical trial is underway to assess the safety and effectiveness of A24110He, a promising drug for patients with type 2 diabetes and elevated triglyceride levels. This phase 2 study aims to evaluate the drug’s safety, local tolerability, and pharmacodynamic profile through multiple doses in a controlled setting. The trial’s findings could potentially lead to improved treatment options for individuals struggling with these conditions.

Related diseases and areas:

• Hypertriglyceridaemia
• Type 2 diabetes mellitus

A3907

A3907 is an investigational drug being studied for the treatment of Primary Sclerosing Cholangitis (PSC), a chronic liver disease. This article discusses an open-label, Phase 2 clinical trial designed to assess the safety, tolerability, and effects of A3907 in adults with PSC. The study aims to evaluate different dosages of A3907 and its impact on bile acid levels, liver enzymes, and other relevant biomarkers in patients with PSC.

Related diseases and areas:

• Cholangitis sclerosing

A49

A groundbreaking clinical trial is underway to evaluate the effectiveness of a new adjuvant vaccine, known as A49, for patients with glioblastoma. This Phase 1/2a study, called NAVIG-1, aims to assess the safety, immune response, and potential benefits of A49 in combination with other treatments for this aggressive form of brain cancer. The trial focuses on patients who have already undergone initial treatment and seeks to improve their outcomes through this innovative approach.

Related diseases and areas:

• Glioblastoma

A52

A new clinical trial is underway to investigate the potential of A52, a peptide-based vaccine, in treating glioblastoma, an aggressive form of brain cancer. This study, known as NAVIG-1, aims to evaluate the safety and effectiveness of A52 when combined with other treatments. The trial focuses on patients who have already undergone initial therapy and seeks to improve their outcomes through this innovative approach.

Related diseases and areas:

• Glioblastoma

Aaa802

AAA802 is an investigational drug currently being studied in clinical trials for the treatment of advanced prostate cancer. This article will provide an overview of the ongoing research, focusing on a Phase I/II clinical trial called “SatisfACtion” that aims to evaluate the safety, tolerability, and effectiveness of AAA802 in patients with metastatic castration-resistant prostate cancer (mCRPC).

Related diseases and areas:

• Prostate cancer

AAV9-CTNT-COBAG3

Clinical trials investigating AAV9-CTNT-COBAG3 are studying an interventional gene-based treatment in adults with BAG3-associated dilated cardiomyopathy. The trials aim to assess safety, tolerability, and possible clinical benefit after a single intravenous infusion. The target population is adult participants with this inherited heart condition.

Aavanc80-3’Hotof

This article discusses the clinical trials of AAVAnc80-hOTOF, a promising gene therapy for individuals with sensorineural hearing loss caused by mutations in the otoferlin gene (OTOF). The trials aim to evaluate the safety, tolerability, and effectiveness of this innovative treatment approach for patients with a specific type of genetic hearing loss.

Related diseases and areas:

• Deafness

Aavanc80-5’Hotof

Clinical trials are currently underway to evaluate the safety and effectiveness of Aavanc80-5’Hotof, a groundbreaking gene therapy designed to treat sensorineural hearing loss caused by mutations in the otoferlin gene (OTOF). This innovative treatment aims to restore hearing in patients with this genetic condition by delivering a functional copy of the OTOF gene directly to the inner ear. The trials involve both initial treatment and long-term follow-up studies to assess the therapy’s safety, efficacy, and potential long-term benefits for patients with this rare form of hearing loss.

Related diseases and areas:

• Deafness

Ab-1002

Clinical trials are investigating Ab-1002 in adults with congestive heart failure and non-ischemic cardiomyopathy. The main goal is to see whether it is safe and whether it can improve heart failure outcomes compared with placebo. The study focuses on people with NYHA Class III symptoms.

Related diseases and areas:

• Dilated cardiomyopathy

Ab-729

Clinical trials are investigating Ab-729 in people with chronic HBV infection. The study data focus on safety, tolerability, and treatment-related reactions in NA-suppressed subjects. These trials help show how Ab-729 is being tested in a Phase 2 setting.

Related diseases and areas:

• Chronic hepatitis B

AB521

Clinical trials investigating AB521 are studying treatment in people with advanced or metastatic clear cell renal cell carcinoma. The main goal is to compare disease control and safety-related outcomes in a Phase 3 trial. These studies focus on patients with this type of kidney cancer who are eligible for randomization.

Abacavir

Clinical trials investigating Abacavir are studying how it is used in people with HIV-1 and in patients with systemic lupus. The trials look at treatment effects, viral control, immune changes, and other outcomes in adults and children. Some studies also include people with perinatal HIV infection or virologically suppressed HIV-1.

Related diseases and areas:

• Systemic lupus erythematosus
• HIV infection

Abatacept

Clinical trials are investigating Abatacept in several diseases, including rheumatoid arthritis, IgG4-related disease, giant cell arteritis, COVID-19, and juvenile idiopathic arthritis. These studies look at safety, effectiveness, remission, and whether Abatacept can help guide treatment choices in different patient groups.

Related diseases and areas:

• Giant cell arteritis
• Psoriatic arthropathy
• Immunoglobulin G4 related d…
• Rheumatoid arthritis
• COVID-19
• Juvenile idiopathic arthritis

Abbv-668

Clinical trials are investigating Abbv-668 in adults with moderate to severe ulcerative colitis. This article explains what the study aimed to measure, who could take part, and which outcomes were tracked, such as safety and endoscopic improvement.

Related diseases and areas:

• Colitis ulcerative

ABBV-8736

Clinical trials are studying ABBV-8736 in adults with moderate to severe Crohn’s disease. These studies aim to check safety, efficacy, and how the treatment affects the disease. The trial data here describe a Phase 2 study in a large adult population.

Related diseases and areas:

• Crohn’s disease

ABBV-CLS-628

Clinical trials are studying ABBV-CLS-628 in adults with autosomal dominant polycystic kidney disease (ADPKD). These trials aim to assess safety and how well the treatment works, including changes in kidney size measured over time.

Related diseases and areas:

• Congenital cystic kidney di…

Abc-15A-116

Clinical trials are underway to assess the safety, tolerability, and immunogenicity of V116, a new 21-valent pneumococcal conjugate vaccine. These studies aim to evaluate V116 in different age groups and populations at increased risk for pneumococcal disease. The trials compare V116 to existing pneumococcal vaccines and measure immune responses and adverse events following vaccination.

Related diseases and areas:

• Pneumococcal infection

Abc-15Bo-116

This article discusses the ongoing clinical trials for V116, a new pneumococcal vaccine developed by Merck & Co. Inc. The trials aim to assess the safety, tolerability, and immune response of V116 in various populations at increased risk of pneumococcal disease, including adults, children, and adolescents. These studies are crucial in determining the potential of V116 as a preventive measure against pneumococcal infections.

Related diseases and areas:

• Pneumococcal infection

Abc-16F-116

Recent clinical trials are investigating the V116 pneumococcal vaccine, a 21-valent conjugate vaccine developed by Merck & Co. Inc. These studies aim to assess the safety, tolerability, and immune response of V116 in various populations at increased risk for pneumococcal disease, including adults, children, and adolescents. The trials compare V116 to existing pneumococcal vaccines and evaluate its potential in preventing pneumococcal infections.

Related diseases and areas:

• Pneumococcal infection

Abc-23A-116

Clinical trials are underway to assess the safety, tolerability, and immunogenicity of V116, a new 21-valent pneumococcal conjugate vaccine. These studies aim to evaluate V116 in various populations at increased risk for pneumococcal disease, including adults, children, and adolescents. The trials compare V116 to existing pneumococcal vaccines and measure immune responses and adverse events following vaccination.

Related diseases and areas:

• Pneumococcal infection

Abc-23B-116

This article discusses the ongoing clinical trials for V116, a new pneumococcal vaccine being developed by Merck & Co. Inc. The trials aim to assess the safety, tolerability, and immune response of V116 in various populations at increased risk for pneumococcal disease, including adults, children, and adolescents. These studies are important for understanding how well V116 protects against pneumococcal infections and its potential as a new preventive option.

Related diseases and areas:

• Pneumococcal infection

Abc-24F-116

Recent clinical trials are investigating the safety, tolerability, and immunogenicity of V116, a new 21-valent pneumococcal conjugate vaccine. These studies aim to assess the vaccine’s potential in preventing pneumococcal disease in various age groups and populations at increased risk. The trials compare V116 to existing pneumococcal vaccines and evaluate immune responses and adverse events following vaccination.

Related diseases and areas:

• Pneumococcal infection

Abc-31-116

Recent clinical trials are investigating the safety, tolerability, and immunogenicity of V116, a new pneumococcal vaccine. These studies focus on different age groups, including adults with increased risk of pneumococcal disease, as well as children and adolescents. The trials aim to compare V116 with existing pneumococcal vaccines and assess its potential in preventing pneumococcal infections.

Related diseases and areas:

• Pneumococcal infection

Abc-35B-116

Clinical trials are currently underway to assess the safety, tolerability, and immunogenicity of V116, a new pneumococcal vaccine. These studies aim to evaluate the vaccine’s effectiveness in various populations, including adults at increased risk of pneumococcal disease, older adults, and children and adolescents with higher risk factors. The trials compare V116 to existing pneumococcal vaccines and measure immune responses and potential side effects.

Related diseases and areas:

• Pneumococcal infection

Abelacimab

Abelacimab is an innovative anticoagulant drug currently being studied in several clinical trials for its potential in treating various medical conditions. These trials aim to evaluate the safety and effectiveness of Abelacimab in preventing blood clots and managing conditions such as atrial fibrillation and cancer-associated venous thromboembolism. The ongoing research seeks to determine if Abelacimab could provide better outcomes compared to existing treatments while maintaining a favorable safety profile.

Related diseases and areas:

• Atrial fibrillation
• Embolism venous

Abemaciclib

Clinical trials are studying Abemaciclib in several cancers, mainly breast cancer and also prostate cancer, glioma, ovarian cancer, lung cancer, and sarcoma. These studies look at safety, effectiveness, and the best treatment combinations for different patient groups, including early, advanced, metastatic, and older patients.

Related diseases and areas:

• Hormone receptor positive H…
• Hormone receptor positive b…
• Ovarian cancer
• Ovarian cancer recurrent
• Ovarian epithelial cancer
• Breast cancer female

Abiraterone

Clinical trials are studying Abiraterone in several types of prostate cancer, including metastatic castration-resistant, metastatic hormone-sensitive, and hormone-naïve disease. These studies look at how well it works, how safe it is in trial settings, and whether it helps with outcomes such as progression-free survival and overall survival in different patient groups.

Related diseases and areas:

• Prostate cancer
• Hormone-dependent prostate …
• Prostate cancer metastatic
• Hormone-refractory prostate…

ABIRATERONE DECANOATE

Clinical trials investigating ABIRATERONE DECANOATE are studying related treatment strategies in prostate cancer, mainly to assess safety and efficacy. The available trial data focus on men with metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer, including people who have not used androgen receptor pathway inhibitors before.

Related diseases and areas:

• Prostate cancer

Abrocitinib

Clinical trials are investigating Abrocitinib in people with eczema and chronic hand eczema. These studies look at safety, how well the treatment works, and how well people can tolerate it. The trials include children, adolescents, and adults with moderate to severe disease.

Related diseases and areas:

• Hand dermatitis
• Dermatitis atopic

Absk021 Hydrochloride Hydrate

ABSK021 Hydrochloride Hydrate is a promising drug being studied in clinical trials for the treatment of Tenosynovial Giant Cell Tumor (TGCT). This article explores the ongoing research to determine its safety and effectiveness in patients with this rare condition. The trials aim to compare ABSK021 with a placebo to assess its impact on tumor response, joint function, and overall quality of life for TGCT patients.

Related diseases and areas:

• Giant cell tumour of tendon…

Abt-494

Clinical trials of Abt-494 are studying its use in adults with axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis. The trials aim to assess how well it works, how safe it is, and how well people tolerate it. They focus on adults with active disease, including some who did not respond to biologic DMARDs.

Related diseases and areas:

• Axial spondyloarthritis
• Ankylosing spondylitis

Ac-Ala-Gly-Ser-Cys(1)-Tyr-Cys(2)-Ser-Gly-Pro-Pro-Arg-Phe-Glu-Cys(2)-Trp-Cys(1)-Tyr-Glu-Thr-Glu-Gly-Thr-Gly-Gly-Gly-Lys(Unk)-Nh2 Conjugated To Cy5 Dye

This article discusses a clinical trial investigating the use of EMI-137, a novel fluorescent tracer, for intraoperative visualization in patients with penile and tongue cancer. The study aims to assess the feasibility of using this c-Met-based receptor-mediated fluorescence imaging technique to improve tumor detection and visualization during surgery. The trial also explores the potential of EMI-137 in identifying lymph node metastases and detecting dysplasia or carcinoma in situ in these types of cancers.

Related diseases and areas:

• Tongue neoplasm malignant s…
• Penile cancer

Acalabrutinib

Clinical trials are studying Acalabrutinib in several blood cancers, especially chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, and diffuse large B-cell lymphoma. These studies look at how well it works, how safe it is, and which patients may benefit most. Many trials include older adults, people with relapsed disease, or patients with newly diagnosed high-risk disease.

Related diseases and areas:

• Chronic lymphocytic leukaem…
• High grade B-cell lymphoma …
• Diffuse large B-cell lymphoma
• B-cell unclassifiable lymph…
• Marginal zone lymphoma
• Chronic lymphocytic leukaemia

ACARBOSE

Clinical trials are investigating ACARBOSE in people with obesity. This article explains what the study tested, who took part, and what outcomes were measured, such as tolerability during dose-escalation and symptom scores. The trial compared ACARBOSE-related treatment strategies with other obesity treatments.

Related diseases and areas:

• Obesity

Acasunlimab

Clinical trials are studying Acasunlimab in several cancer types, including solid tumors, melanoma, and non-small cell lung cancer. These studies look at safety, effectiveness, and the best dose, both alone and with pembrolizumab. The target groups include people with advanced, relapsed, or treatment-resistant cancer.

Related diseases and areas:

• Non-small cell lung cancer
• Malignant melanoma
• Non-small cell lung cancer …
• Neoplasm malignant

Acetazolamide

Clinical trials investigating Acetazolamide are studying how it performs in different patient groups, mainly people with heart failure, lung cancer, and X-linked retinitis pigmentosa. These studies look at safety, tolerability, and treatment effect in specific trial settings. Some trials are phase 1, while others are phase 3.

Related diseases and areas:

• Retinitis pigmentosa
• Clear cell renal cell carci…
• Cardiac failure congestive
• Colorectal cancer
• Lung neoplasm malignant
• Cardiac failure acute

Acetazolamide Sodium

Acetazolamide Sodium, a carbonic anhydrase inhibitor, is currently being studied in clinical trials for its potential benefits in treating normal pressure hydrocephalus (NPH). This article explores the ongoing research, focusing on a double-blind randomized trial that aims to evaluate the effects of acetazolamide on gait, symptoms, and quality of life in NPH patients. We’ll discuss the trial’s objectives, eligibility criteria, and expected outcomes, providing valuable insights into this promising treatment approach.

Related diseases and areas:

• Normal pressure hydrocephalus

Acetic Acid, Glacial

A clinical trial is currently underway to investigate the effectiveness of Acetic Acid, Glacial in treating skin ulcers with biofilm. This study aims to compare the healing process of ulcers treated with acetic acid to a control group, focusing on changes in ulcer size, healing time, and overall patient outcomes. The trial involves 104 patients and will assess various aspects of ulcer healing over a 12-week period.

Related diseases and areas:

• Skin ulcer

ACETYLCARNITINE HYDROCHLORIDE

Clinical trials are investigating ACETYLCARNITINE HYDROCHLORIDE in people with amyotrophic lateral sclerosis (ALS). These studies aim to measure whether it can help slow loss of function and improve self-sufficiency, while also looking at treatment effects in patient groups with this disease.

Related diseases and areas:

• Amyotrophic lateral sclerosis